Vol 91, No 2 (2020)
Clinical vignette
Published online: 2020-02-12
Unusually high plasma values of many tumour markers in a patient with idiopathic pulmonary fibrosis
12
, 2, 3, 3, 4, 12
, 2, 3, 3, 4, 12
Abstract
Not available
References
- Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017; 3: 17074.
- Raghu G, Remy-Jardin M, Myers JL, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5): 44–68.
- Fujita J, Obayashi Y, Yamadori I, et al. Marked elevation of CA19-9 in a patient with idiopathic pulmonary fibrosis: CA19-9 as a bad prognostic factor. Respirology. 1998; 3(3): 211–214.
- Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017; 5(12): 946–955.
- Rusanov V, Kramer MR, Raviv Y, et al. The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation. Chest. 2012; 141(4): 1047–1054.
